logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Wanbury Ltd

Wanbury

Small Cap•1,382 Employees•IPO 1992
Current Price
₹255.70
-7.58 (-2.88%)Updated
NSE :WANBURY
BSE :524212
Sector :Pharmaceuticals
Today's Range
₹252.75
₹255.70
union icon
₹265.00
52 Week Range
52W Low₹161.50
52W High₹329.70
₹255.70
union icon
Downside58.33%
Upside28.94%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹903.32 Cr
Market Cap
Total market value of company
P/E Ratio
18.01
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
8.28
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹14.97
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
42.57%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
36.70%
ROCE
Return on Capital Employed. >15% is good
Net Margin
7.98%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-19.68%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
8.90%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
24.50%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
1197.00%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
2.98
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹18.09
Book Value
Net asset value per share
Dividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
43.10%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • •Astounding 1197% quarterly profit growth indicates robust operational efficiency and strong turnaround.
  • •Impressive Return on Equity (ROE) of 76.50% demonstrates excellent profit generation from shareholder investments.

Weaknesses

5 points
  • •High debt-to-equity ratio of 2.98 indicates substantial financial leverage and associated risks.
  • •Negative long-term EPS growth over 3Y (-29.12%) and 5Y (-19.68%) is concerning.

Opportunities

5 points
  • •Operating in the growing Pharmaceuticals sector, benefiting from increasing healthcare demand.
  • •Strong quarterly sales growth (24.50%) and high ROCE (36.70%) enable market share expansion.

Threats

4 points
  • •Stiff competition from larger, well-established peers like Sun Pharma and Cipla.
  • •Highly regulated industry faces risks from adverse policy changes and pricing controls.

Segment-wise Financial Analysis

Financial Results

Balance Sheet

Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format

No Balance Sheet Data Available

Standalone annual data is not available for this symbol.
Try switching to Consolidated view.

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹287.38+₹31.68+12.39%
R3₹275.13+₹19.43+7.60%
R2₹270.07+₹14.37+5.62%
R1₹262.88+₹7.18+2.81%
PIVOT₹257.822.120.83%
CURRENT₹255.70--
S1₹226.13-₹29.57-11.56%
S2₹238.38-₹17.32-6.77%
S3₹245.57-₹10.13-3.96%
S4₹250.63-₹5.07-1.98%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
1.00L
(25 Feb 2026)
-48.8% vs avg
Delivery %
71.2%
(25 Feb 2026)
+20.4% vs avg
Avg Volume (20D)
1.95L
(30 Jan - 25 Feb)
20-day average
Avg Delivery %
50.7%
(30 Jan - 25 Feb)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Ind-Swift Laboratories Ltd
833.00 %
Highest Dividend Yield
Kopran Ltd
2.26 %

Peer Comparison

Company Name
AHCL
ANUHPHR
Anuh Pharma Ltd
BAJAJHCARE
Bajaj Healthcare Ltd
BETA
Beta Drugs Ltd
INDSWFTLAB
Ind-Swift Laboratories Ltd
KILITCH
Kilitch Drugs (India) Ltd
KOPRAN
Kopran Ltd
LINCOLN
Lincoln Pharmaceuticals Ltd
NGLFINE
NGL Fine Chem Ltd
SAKAR
Sakar Healthcare Ltd
SIGACHI
Sigachi Industries Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
THEMISMED
Themis Medicare Ltd
VENUSREM
Venus Remedies Ltd

About

WANBURY

Wanbury Ltd

Wanbury Limited is a pharmaceutical company based in Navi Mumbai, India, established in 1988 (formerly known as Pearl Organics Limited). The company's core business is the manufacturing and sale of both pharmaceutical formulations and active pharmaceutical ingredients (APIs). This dual approach allows for vertical integration within their supply chain, potentially increasing efficiency and control over product quality and cost.

Wanbury's formulations cater to a broad range of therapeutic areas. Their product portfolio includes medications for gynecological conditions, orthopedic issues, hematological disorders (related to blood), diabetes, gastrointestinal problems, stroke recovery, and common ailments like coughs and colds. Additionally, they offer formulations addressing pain (analgesics), inflammation (anti-inflammatories), and other general practitioner needs. The diversification across therapeutic areas likely reflects a strategy to mitigate risk and tap into various market segments.

Complementing their formulations business, Wanbury also produces a significant range of APIs. These are the fundamental chemical compounds used to create finished pharmaceutical products. Wanbury's API production focuses on key therapeutic areas, including diabetes (anti-diabetic APIs), pain relief (anti-analgesic APIs), depression (anti-depressant APIs), allergies (anti-histaminic APIs), inflammation and arthritis (anti-inflammatory and anti-arthritis APIs), blood clotting disorders (anti-thrombotic APIs), epilepsy (anti-epileptic APIs), and high blood pressure (anti-hypertensive APIs). This API production provides a strong foundation for their own formulations and also allows them to potentially supply other pharmaceutical companies.

In summary, Wanbury's business model integrates both the manufacturing of formulations for direct sale and the production of APIs, a crucial component in the pharmaceutical industry's supply chain. Their extensive product portfolio targeting diverse therapeutic areas demonstrates a strategy for market diversification and sustained growth. Their presence both domestically in India and internationally positions them within a global pharmaceutical landscape.

COMPANY FACTS - WANBURY

Registered Address

BSEL Techpark, B' Wing, 10th Floor, Sector 30-A, Opp. Vashi Railway Station, Vashi

Navi Mumbai

MAHARASHTRA

IN

Tel: 912267942222

Website:http://www.wanbury.com/

Investor Relations:https://ess.wanbury.com/wanbury/www/inv-griev.html
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 1,382

IPO Date: 24/02/1992

MANAGEMENT - WANBURY

Mr. K. Chandran

Vice Chairman of the Board

Mr. Vinod Verma

Chief Financial Officer

Mr. Jitendra Gandhi

Compliance Officer, Company Secretary

Mr. Manojkumar Khubchand Gursahani

Non-Executive Independent Director

Mr. Mridul Mehta

Non-Executive Independent Director

Ms. Anupama Vaidya

Non-Executive Independent Director

Mr. Pallavur Sankar Dass Vaidyanathan

Additional Non-Executive Independent Director

Investor Questions Answered

Wanbury Ltd (WANBURY) Stock FAQs

Get answers to the most common questions about Wanbury Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Wanbury Ltd (WANBURY) is ₹255.7. Today, the stock has declined by ₹7.58 (2.88%), trading in a range of ₹252.75 to ₹265. The stock opened at ₹261 with a trading volume of 99,613 shares.
Wanbury Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹903.32 crores, P/E ratio of 18.01, ROE of 42.57%, and ROCE of 36.70%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Wanbury Ltd (WANBURY) is ₹329.7, while the 52-week low is ₹161.5. Currently trading at ₹255.7, the stock is 56.0% away from its 52-week low and 22.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Wanbury Ltd stock at ₹255.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 18.01 and P/B ratio of N/A. Today's performance shows a loss of 2.88%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Wanbury Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹255.7, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Wanbury Ltd's key financial metrics include: P/E Ratio: 18.01, P/B Ratio: N/A, ROE: 42.57%, ROCE: 36.70%, Dividend Yield: 0.00%, EPS: ₹14.97, Book Value: ₹18.09, Debt-to-Equity: 2.98, and Current Ratio: N/A. The company's market cap stands at ₹903.32 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Wanbury Ltd stock opened at ₹261 and is currently trading at ₹255.7, showing a decline of ₹7.58 (2.88%). The intraday high is ₹265 and low is ₹252.75. The trading volume stands at 99,613 shares, indicating moderate market participation today.
Wanbury Ltd has a Price-to-Earnings (P/E) ratio of 18.01, which means investors are willing to pay ₹18.01 for every ₹1 of earnings. With an EPS of ₹14.97, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Wanbury Ltd has a market capitalization of ₹903.32 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹255.7) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Wanbury Ltd has a book value of ₹18.09 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹255.7, which is 1313.5% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Wanbury Ltd has a Return on Equity (ROE) of 42.57% and Return on Capital Employed (ROCE) of 36.70%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. Both metrics are strong, indicating efficient capital utilization. Higher percentages generally indicate better financial performance.
Wanbury Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Wanbury Ltd has a debt-to-equity ratio of 2.98, which measures the company's financial leverage by comparing total debt to shareholders' equity. A ratio above 2 indicates high leverage and potentially higher financial risk. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Wanbury Ltd has an Earnings Per Share (EPS) of ₹14.97, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹255.7 and P/E ratio of 18.01, investors are paying 18.01 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Wanbury Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Wanbury Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Wanbury Ltd stock, consider: 1) Fundamental Analysis - Review P/E (18.01), ROE (42.57%), debt-to-equity (2.98), and growth rates. 2) Technical Analysis - Check 52-week range (₹161.50 - ₹329.70), moving averages, and chart patterns. 3) Valuation - Compare current price (₹255.70) with book value (₹18.09) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Wanbury Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹255.7 is 2457x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Wanbury Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹161.50 - ₹329.70). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 2.98 indicates leverage. 4) Liquidity Risk - Based on trading volume of 99,613 shares. 5) Valuation Risk - P/E of 18.01 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Wanbury Ltd operates in the industry with key metrics: P/E ratio of 18.01, ROE of 42.57%, market cap of ₹903.32 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 2.98), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Wanbury Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹255.7, with a 52-week range of ₹161.50 to ₹329.70. Based on fundamentals like P/E (18.01), ROE (42.57%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Wanbury Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹255.70. 2) Fundamental Deterioration - Declining ROE (currently 42.57%), increasing debt (D/E: 2.98), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Wanbury Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.